# Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects

> **NCT00698568** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 7460 (actual)

## Conditions studied

- Prophylaxis for Herpes Simplex

## Interventions

- **BIOLOGICAL:** Herpes simplex candidate vaccine- adjuvanted GSK 208141
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00698568
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-10
- **Primary completion:** 1999-04
- **Final completion:** 1999-04
- **Target enrollment:** 7460 (ACTUAL)
- **Last updated:** 2008-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00698568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00698568, "Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00698568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*